Searchable abstracts of presentations at key conferences in endocrinology

ea0007p89 | Endocrine tumours and neoplasia | BES2004

The GnRH test in the assessment of patients with pituitary and parapituitary lesions. Results of a 5-year retrospective study

Chammas N , Chambers S , Harris P

This study is designed to test the hypothesis that the gonadotrophinresponses to GnRH are heterogeneous and that, in pituitary/parapituitary lesion patients, the test is of no value as a diagnostic discriminator.We carried out a 5-year retrospective review of GnRH results from a cohort of 104 male (46) and female (premenopausal 49, post-menopausal 9) patients with pituitary/parapituitary lesions. Serum LH and FSH levels were measur...

ea0009oc19 | Oral Communication 3: Neuroendocrinology | BES2005

The nadir growth hormone after an octreotide test dose predicts the long term efficacy of somatostatin analogue therapy in acromegaly

Gilbert J , Miell J , Chambers S , McGregor A , Aylwin S

Treatment of acromegaly aims primarily to reverse the increased mortality and morbidity associated with active disease to that of the non-acromegalic population. Recent evidence indicates that the best biochemical criteria for successful treatment should be a mean GH<2micrograms per litre (approximately 4milliunits per litre). Although a 'test dose' of octreotide (OTD) is recommended prior to use of depot somatostatin analogues (SSAs), there remains no consensus regarding t...

ea0011p191 | Clinical practise and governance | ECE2006

Concordance between GH determination and IGF-I in acromegaly using two IGF-I methods

Hepburn S , Chambers SM , Gilbert JA , McGregor AM , Miell JP , Aylwin SJB

Introduction and aims: Following treatment for acromegaly, both growth hormone (GH) and insulin-like growth factor-I (IGF-I) levels are predictive of mortality. These data are derived from studies of either a single GH or the mean circadian GH, with a threshold of 2 mcg/l. However, consensus target criteria (Giustina et al. 2000) require: a nadir GH of <1 mcg/l on OGTT and IGF-I within the age/sex-adjusted normal range. We aimed to determine the degree to which norm...

ea0011p200 | Clinical practise and governance | ECE2006

Is a repeat or resting prolactin necessary in the investigation of hyperprolactinaemia?

Agarwal R , Pramodh S , Durroch P , Chambers S , McGregor A , Aylwin SJB

Background: Prolactin levels are affected by stress, and in patients with moderate hyperprolactinaemia, a repeat test and/or a resting prolactin has been recommended, but there are very few data addressing the utility of these additional measurements.Aim: To study the value of: A) Repeat measurement and B) Resting measurement of serum prolactin in mild to moderate prolactin excess (510–7500 IU/L).Methods and subjects: Case not...

ea0010p42 | Endocrine tumours and neoplasia | SFE2005

Octreotide in the treatment of pthrp related hypercalcaemia in neuroendocrine tumours: a case report and literature review

Jones R , OaGrady J , Chambers S , Heaton N , Ramage J , Aylwin S

Intro: A subset of pancreatic and gastric neuroendocrine tumours (NET) are associated with hypercalcaemia attributed to tumour secretion of parathyroid hormone related peptide (PTHrP). Hypercalcaemia may be severe and refractory to conventional treatment....